FDA gives over-the-counter infant oxygen monitors their own device class

The Food and Drug Administration has established a formal device category for a product many parents already own: the over-the-counter monitor that clips or straps to a baby and reports its pulse and blood-oxygen level. A final order published in the Federal Register on 9 October 2026 classifies the "infant pulse rate and oxygen saturation monitor for over-the-counter use" into class II, the agency's middle risk tier, with special controls attached [s1].

The order amends 21 CFR part 870 and adds a new section, 870.2705, under docket FDA-2026-N-10993. It took effect on 9 October 2026, with the classification applicable from an earlier date, 8 November 2023 [s1].

What the device is

The rule names the generic type and defines it tightly. It is "a device that uses photoplethysmography to measure pulse rate and oxygen saturation in infants," and it "may contain alarms that alert the caregiver when vital sign(s) go outside preset threshold(s)" [s1]. Photoplethysmography is the optical technique behind familiar fingertip pulse oximeters: a light is shone through tissue and the device reads how much is absorbed as blood pulses through, inferring heart rate and oxygen saturation from the pattern.

The phrase that matters most is "over-the-counter." This is a device meant to be bought and used by caregivers at home without a prescription or clinical supervision — the category that has grown up around sock-style and clip-style baby monitors sold to watch a sleeping infant's vital signs.

Out of class III, into class II

As with other novel devices, the starting point was the strictest tier. Any device not in commercial distribution before 28 May 1976 is automatically assigned to class III — which ordinarily requires premarket approval — and remains there by operation of law until the FDA reclassifies it [s1]. The agency moved this device type down through the De Novo pathway, the process for novel lower-risk devices with no existing predicate, under which it must classify the device by written order within 120 days [s1].

Settling the type in class II, the FDA says, provides a reasonable assurance of safety and effectiveness while enhancing access to beneficial innovation, "in part by reducing regulatory burdens by placing the device into a lower device class than the automatic class III assignment" [s1]. The effect is to give makers of equivalent OTC infant monitors a clearer route — a 510(k) clearance measured against the special controls — rather than full premarket approval.

The risk the controls are built around

The order does not treat these monitors as trivial. The FDA identifies the risks to health and the measures required to mitigate them, and the lead risk is a "poor quality incoming photoplethysmography signal resulting in failure to detect pulse" — the scenario in which the sensor is reading badly and misses a real problem [s1]. Against that risk the order requires clinical performance testing and human factors testing, the latter being the study of whether ordinary caregivers can use the device correctly in real conditions [s1].

That pairing is the heart of the rule. A home monitor that quietly fails to register a drop could give a false reassurance that is worse than no monitor at all, and a device whose alarm is confusing to a tired parent at 3 a.m. is a safety problem in its own right. The special controls are an attempt to force both failure modes — the measurement and the human use of it — into the evidence a manufacturer has to produce. The order notes that the special controls it sets out will become part of the codified language for the device type, so they bind not just the sponsor that prompted the classification but any later maker that seeks to market an equivalent monitor under the same category [s1].

Why it matters

Consumer baby oxygen monitors have occupied an awkward space, marketed in many cases as wellness gadgets rather than regulated medical devices. By defining an over-the-counter device type and tying it to clinical and human-factors testing, the FDA has drawn these products into its device framework and set the terms future versions must meet. The order is final and in effect; it does not recall or endorse any particular product, but it fixes the standard the category will now be held to [s1].